19 days ago
SYRE
AnalystsDavid HoangDavid Hoang's Stock Forecasts
AnalystsDavid Hoang
Sectors:
Analyst Ranking
Top 9%
#425 out of 5266 analysts
Average Return
+24.09%
Win Rate
64%29 out of 45
Risk vs Reward
Poor
Good
David Hoang's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Spyre Therapeutics IncSYRE | +327.46% | $16.24 | $69.42 | 2025-09-25 - 2026-05-01 | Strong Buy |
Praxis Precision Medicines IncPRAX | +280.44% | $84.24 | $320.48 | 2025-02-10 - 2026-02-10 | Strong Buy |
Longboard Pharmaceuticals IncLBPH | +181.99% | $21.27 | $59.98 | 2024-02-15 - 2024-11-29 | Strong Buy |
Avadel Pharmaceuticals PLCAVDL | +140.33% | $9.00 | $21.63 | 2025-02-10 - 2026-02-10 | Strong Buy |
Longboard Pharmaceuticals IncLBPH | +95.12% | $30.74 | $59.98 | 2024-07-01 - 2024-11-29 | Strong Buy |
David Hoang Analyst Color
Get additional color on David Hoang's coverage of popular stocks
2 months ago
XENE
7 months ago
PRAX
10 months ago
HRMY
a year ago
ALKS
2 years ago
SRPT
David Hoang's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Spyre Therapeutics IncSYRE | 2 | Strong Buy | $88.00 | +26.76% | Maintains | 19 days ago |
Ataibeckley IncATAI | 1 | Strong Buy | $12.00 | +189.86% | Initiates Coverage On | a month ago |
Xenon Pharmaceuticals IncXENE | 4 | Strong Buy | $90.00 | +60.34% | Maintains | 2 months ago |
Apogee Therapeutics IncAPGE | 1 | Strong Buy | $103.00 | +27.55% | Initiates Coverage On | 5 months ago |
Alkermes PLCALKS | 3 | Strong Buy | $45.00 | +34.81% | Maintains | 6 months ago |
Praxis Precision Medicines IncPRAX | 2 | Strong Buy | $280.00 | -13.63% | Maintains | 7 months ago |
Harmony Biosciences Holdings IncHRMY | 4 | Strong Buy | $36.00 | +13.10% | Maintains | 7 months ago |
Sarepta Therapeutics IncSRPT | 10 | Strong Sell | $12.00 | -44.16% | Maintains | 9 months ago |
Acadia Pharmaceuticals IncACAD | 5 | Strong Buy | $35.00 | +59.45% | Upgrades | a year ago |
Denali Therapeutics IncDNLI | 3 | Strong Buy | $31.00 | N/A | Initiates Coverage On | a year ago |
Biohaven LtdBHVN | 1 | Strong Buy | $65.00 | N/A | Initiates Coverage On | a year ago |
Axsome Therapeutics IncAXSM | 4 | Strong Buy | $176.00 | N/A | Initiates Coverage On | a year ago |
Avadel Pharmaceuticals PLCAVDL | 1 | Strong Buy | $12.00 | N/A | Initiates Coverage On | a year ago |
Neurocrine Biosciences IncNBIX | 4 | Hold | $158.00 | N/A | Maintains | 2 years ago |
Longboard Pharmaceuticals IncLBPH | 3 | Strong Buy | $50.00 | N/A | Maintains | 2 years ago |
Acumen Pharmaceuticals IncABOS | 1 | Strong Buy | $7.00 | N/A | Initiates Coverage On | 2 years ago |
Sage Therapeutics IncSAGE | 1 | Strong Sell | $8.00 | N/A | Initiates Coverage On | 2 years ago |
Solid Biosciences IncSLDB | 1 | Strong Buy | $16.00 | N/A | Initiates Coverage On | 2 years ago |
Voyager Therapeutics IncVYGR | 1 | Strong Buy | $16.00 | N/A | Initiates Coverage On | 2 years ago |
Alnylam Pharmaceuticals IncALNY | 1 | Hold | $220.00 | N/A | Initiates Coverage On | 3 years ago |
Arrowhead Pharmaceuticals IncARWR | 1 | Buy | $80.00 | N/A | Initiates Coverage On | 3 years ago |
Provention Bio IncPRVB | 1 | Hold | $25.00 | N/A | Downgrades | 3 years ago |
Gossamer Bio IncGOSS | 1 | Hold | $3.00 | N/A | Downgrades | 3 years ago |
Orchard Therapeutics PLCORTX | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.